Optos plc Total Voting Rights (0051M)
01 Mai 2015 - 11:25AM
UK Regulatory
TIDMOPTS
RNS Number : 0051M
Optos plc
01 May 2015
OPTOS PLC
("Optos" or the "Company" or the "Group")
Total Voting Rights and Issued Share Capital
LONDON - 1 May 2015: Optos plc (LSE: OPTS) confirms that, in
accordance with the provisions of the Financial Conduct Authority's
("FCA") Disclosure Rules and Transparency Rules ("DTR" or the
"Rules"), as at 30 April 2015, the Company had an issued share
capital of 73,145,765 Ordinary Shares of GBP0.02 per share which
are admitted to trading and which carry the right to one vote at
general meetings of the Company. The Company holds no shares in
treasury. Therefore, the total number of voting rights in the
Company is 73,145,765.This figure may be used by shareholders as
the denominator for the calculations by which they will determine
whether they are required to notify their interest in, or a change
to their interest in, the Optos plc under the FCA's Disclosure
Rules and Transparency Rules.
< ENDS >
Enquiries
Optos plc
Robert Kennedy, Chief Financial Officer and Company
Secretary.
+44 (0)1383 843 300
About Optos Plc
Optos plc has the vision to be The retina company. We aim to be
recognised as a leading provider of devices and solutions to
eyecare professionals for improved patient care. Optos' core
devices produce ultra widefield, high resolution digital images
(optomaps(R)) of approximately 82% of the retina, something no
other device is capable of doing in any one image. Our recent
acquisition of OPKO instrumentation brings the group optical
coherence tomography ("OCT") diagnostic devices and optical
ultrasound scanners, used in the diagnosis and management of eye
disease and conditions.
Optos' widefield retinal imaging technology, combined with the
specific data that can be derived from OCT images, has the
potential to offer ophthalmologists and optometrists the most
powerful tools for disease diagnosis and management.The optomap
images provide enhanced clinical information which facilitates the
early detection, management and treatment of disorders and diseases
evidenced in the retina such as retinal detachments and tears,
glaucoma, diabetic retinopathy and age-related macular
degeneration. Retinal imaging can also indicate evidence of non-eye
or systemic diseases such as hypertension and certain cancers. OCT
delivers an image that shows a three dimensional, cross-sectional
view of the retina in any particular area, typically in the central
pole area of the retina around the optic nerve and macula and is
used to detect the presence of and understand the severity of
disease, determine treatment approaches and monitor post-treatment
effect.
Optos has a range of imaging devices that support different
customer segments and patient levels: the P200 and 200Dx devices
are concentrated on wellness screening carried out by optometrists
and ophthalmologists in primary care; the P200C devices are
designed to meet the need for more exacting clinical imaging
capabilities and standards in secondary care within the
ophthalmology market and at optometric practices that are
clinically managing a patient base with advanced ocular disease;
and the P200MA and 200Tx devices supports ophthalmologists and
retinal specialists in the medical care market. Our expanded
product range includes visual acuity, perimetry and treatment laser
products.
For more information please visit our website www.optos.com
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates and projections about its industry, its beliefs and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties and other factors, some
of which are beyond the Company's control, are difficult to predict
and could cause actual results to differ materially from those
expressed or forecasted in the forward-looking statements. The
Company cautions shareholders and prospective shareholders not to
place undue reliance on these forward-looking statements, which
reflect the view of the Company only as of the date of this
announcement. The forward-looking statements made in this
announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRUGUPPAUPAUBG
Optos (LSE:OPTS)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Optos (LSE:OPTS)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024